Intradermal hepatitis B vaccination in thalassaemia

Area of Science:

• Immunology
• Vaccinology
• Hepatology

Background:

• Previous intramuscular vaccination with hepatitis B vaccine (HB-VAX) was administered three years prior.
• Study participants included 56 children with thalassaemia and 118 healthy subjects.
• Assessed immune response following booster doses of hepatitis B vaccine.

Purpose of the Study:

• To evaluate the efficacy of intradermal booster doses of hepatitis B vaccine.
• To determine the immune response in both responders and non-responders to initial vaccination.
• To assess the potential of low-dose intradermal vaccination for hepatitis B virus (HBV) immunity.

Main Methods:

• Participants received intradermal booster doses of hepatitis B vaccine.
• Hepatitis B surface (HBs) antibody titres were measured to assess immune response.
• Delayed tissue hypersensitivity reactions were monitored.
• Non-responders received additional doses (two to four) at 15-day intervals.

Main Results:

• All responders showed a significant increase in anti-HBs antibody titres, often exceeding 1000 U/l.
• Non-responders demonstrated a positive HBs antibody response after subsequent intradermal doses.
• Humoral response was consistently preceded by a delayed tissue hypersensitivity reaction.

Conclusions:

• Low-dose intradermal hepatitis B vaccine administration elicits an effective immune response.
• Intradermal vaccination is a valuable strategy for enhancing antibody response in previously exposed individuals.
• This method offers a viable option for vaccinating individuals who initially do not respond to conventional hepatitis B vaccination schedules.